Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-electroporated Dendritic Cell Vaccination in Myeloid Malignancies and Myeloma
NCT00965224Phase 2Completed
- Start
- Jan 2010
- Primary completion
- Dec 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM). Started Jan 2010; status: completed.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00965224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965224.